BIO leadership shakeup followed clashes with board POLITICO's Pulse Check

The leading industry group for biopharmaceutical companies is reeling after the departure of its CEO — just as the Biden administration is poised to begin implementing a new law aimed at reducing drug prices and as the balance of power could shift in Congress. Megan Wilson talks with Katherine Ellen Foley about the turmoil at the industry group. Plus, Chris Hammond, a Covid long-hauler, shares what life has been like for him, the Johns Hopkins trials he's a part of, and why he's not optimistic about additional Covid funding from Congress.